RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses. Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/@RADoctor @RheumNow https://t.co/8gY9ocLBDp

• https://twitter.com/drdavidliew/status/1801641070629109908/photo/1

#opportunistic inf in #autoimmune dz 🎤 @khyrich 👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸) 👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6 👉 🙅‍♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️ 🔗#eular 2022 guide: https://t.co/PIpGpTrH28 #eular2024 #rheumx @RheumNow https://t.co/kouXvradiC

• https://ard.bmj.com/content/annrheumdis/82/6/742.full.pdf
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1

Approach to TB screening prior to commencing biologics. Hyrich K #EULAR2024 @RheumNow https://t.co/j3PI0PHpqW

• https://twitter.com/synovialjoints/status/1801596567758967036/photo/1

Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A

• https://twitter.com/i/web/status/1801590870908518546
• https://twitter.com/synovialjoints/status/1801590870908518546/photo/1

#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly

• EULAR 2024 Daily Recap: Days 1 & 2
• https://twitter.com/Yuz6Yusof/status/1801555153968882024/photo/1

#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM

• https://twitter.com/Yuz6Yusof/status/1801553211758633253/photo/1
• https://twitter.com/Yuz6Yusof/status/1801553211758633253/photo/1

#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo

• https://twitter.com/Yuz6Yusof/status/1801347418086326323/photo/1

Does TCZ switch off GCA histopathologically? GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat) Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary #EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0

• https://twitter.com/drdavidliew/status/1801548741305880971/photo/1
• https://twitter.com/drdavidliew/status/1801548741305880971/photo/1
• https://twitter.com/drdavidliew/status/1801548741305880971/photo/1

Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T